ST-1535

Research use only, not for human use.

A potent, selective A2A adenosine receptor antagonist with Ki of 6.6 nM.

A potent, selective A2A adenosine receptor antagonist with Ki of 6.6 nM; displays 10, 58 and >160-fold selectivity over A1, A2B and A3 receptors, respectively; increases locomotor activity in animal models of Parkinson?s disease.

——

Animal Model:5-6 weeks CD1 male mice Dosage:0, 5, 10 mg/kg Administration:P.o.Result:Antagonized catalepsy induced by i.c.v. administration with the A2A adenosine agonist CGS 21680.Animal Model:Male Sprague Dawley rats Dosage:10, 20, 40mg/kg Administration:I.p. Result:Significantly increased the number of contralateral turns induced by l-DOPA (3 mg/kg i.p.) at 20 and 40 mg/kg.

ST 1535 | ST1535

Apoptosis

Adenosine Receptor

Adenosine Receptor

——

——

496955-42-1

272.316

C12H16N8

>98% (HPLC)

——

NC1=C2N=C(N3N=CC=N3)N(C)C2=NC(CCCC)=N1

2-butyl-9-methyl-8-(2H-1,2,3-triazol-2-yl)-9H-purin-6-amine

(-20℃)

With Ice Pack

≥ 2 years